| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 24 May 2024 | 14 May 2024 |
| GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2024 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31 2024 and to consider and recommend dividend if any on Equity shares for the year ended March 31 2024. Please find enclosed financial results for the quarter and year ended March 31, 2024 along with recommendation of dividend. (As Per BSE Announcement Dated on 24.05.2024) | ||
| Board Meeting | 14 Feb 2024 | 30 Jan 2024 |
| GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31 2023. Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting, approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2023. The said meeting of the Board commenced at 2.00 p.m. and concluded at 06:20 p.m. The copy of the said results and Limited Review Report of Auditors is enclosed herewith. These are also being made available on the website of the Company (As Per BSE Announcement Dated on 14/02/2024) | ||
| Board Meeting | 10 Nov 2023 | 31 Oct 2023 |
| GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2023. Intimation for closure of trading window Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Second Quarter and Half Year ended 30th September, 2023. The said Board Meeting commenced at 02:00 p.m. and ended at 06:40 p.m. The copy of the said results and Limited Review Report of Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com. (As per BSE Announcement Dated on 10/11/2023) | ||
| Board Meeting | 5 Oct 2023 | 5 Oct 2023 |
| The Board of Directors of the Company at its meeting held today, October 05, 2023 have decided to seek the consent of the Members by way of special resolution through Postal Ballot Process for the following: 1. To consider and approve the Sale of Equity Shares of Glenmark Life Sciences Limited, a material subsidiary of the Company. The Board of Directors have appointed Mr. Surjan Singh Rauthan, Practicing Company Secretary, who has given his consent to act as the Scrutinizer, for conducting Postal Ballot process in fair and transparent manner. The meeting commenced at 05:00 p.m. IST and concluded at 05:29 p.m. IST. | ||
| Board Meeting | 21 Sep 2023 | 21 Sep 2023 |
| Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 | ||
| Board Meeting | 11 Aug 2023 | 31 Jul 2023 |
| GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the First quarter ended June 30 2023. Unaudited Financial Results (Standalone and Consolidated) for the First Quarter ended 30th June, 2023 Re-appointment of Ms. Sona Saira Ramasastry (DIN 08398547) as Non-Executive Independent Director (As Per BSE Announcement Dated on 11.08.2023) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
